Company intelligence / Profile preview
Ingenium Therapeutics
Daejeon, Daejeon, South Koreaingeniumcell.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ingenium Therapeutics is a clinical-stage biotechnology company focused on off-the-shelf, allogeneic NK cell therapies. Its lead asset, Gengleucel/IGNK001, has demonstrated favorable safety and efficacy in high-risk AML and MDS populations. The product has received Orphan Drug Designation from the FDA for AML. U.S. Phase 2 trials are set to begin in early 2026 targeting minimal residual disease-positive AML patients; Korean phase 2 approval already obtained. The company is also advancing next-generation gene-inserted CAR-NK therapies for solid tumors
- Therapeutic areas
- OncologyHematology
- Modalities
- NK cell therapyCell therapyGene-inserted CAR-NK cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Transferring manufacturing technology to a Texas-based facility for U.S. clinical supply; other global partnerships referenced but not named specifically.
Beyond the preview
Go deeper on Ingenium Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ingenium Therapeutics.